pills-384846_960_720-300x200-4567758An outside analysis of New York’s spending on prescription drugs for Medicaid recipients raises questions about how the Cuomo administration is enforcing a newly enacted cap on those costs.

The analysis by the Menges Group, which was commissioned by the Pharmaceutical Research and Manufacturers of America, challenges the state’s projection that Medicaid drug costs will increase by 15 percent in the 2017-18 fiscal year.

Menges found that year-to-year growth in the state’s drug costs slowed dramatically after a spike in fiscal year 2015—and actually declined by 4 percent in fiscal year 2017 when rebates were factored in.

The study further cites the federal Centers for Medicare & Medicaid Services, which projects drug costs nationwide will grow at 6 to 7 percent, and statistics from major pharmacy benefit managers, which saw single-digit growth in Medicaid costs in 2016.

“Based on New York’s recent expenditure and growth trends, double-digit escalation in New York’s Medicaid prescription drug expenditures seems unlikely to occur in 2018,” the Menges report said.

The findings contrast sharply with an official forecast from the state Health Department, based in part on projections by the actuarial firm Mercer, which estimate 15 percent growth in the state’s Medicaid drug costs for fiscal year 2018.

(The Cuomo administration previously used exaggerated numbers to describe past drug costs—asserting they had jumped $1.7 billion in three years, when manufacturer rebates had reduced that amount by almost half.)

The state’s growth forecast plays a central role in enforcing the cap on Medicaid drug spending that was adopted last year as part of the state budget. The new law prescribes a maximum spending target for this fiscal year and next. If drug costs exceed that amount, the Health Department is instructed to identify high-cost drugs and seek additional rebates from manufacturers. If drug makers balk, the department is empowered to demand detailed information about they set prices, including records of a company’s research, manufacturing and marketing costs for the drugs in question.

Based on its 15 percent growth rate, officials expect to exceed this year’s cap by $119 million, or more than 12 percent.

The debate highlights some intriguing features of how the cap is working in practice:

First, the cap is much tighter than it appears at first glance.

Growth for fiscal year 2018—as specified in Section 280 of the Public Health Law—is limited to the 10-year rolling average of the medical inflation rate (currently 3.2 percent), plus five percentage points, minus $55 million. That sounds as if it allows a greater-than-inflation increase. To the contrary, the result of that formula, when applied to the state’s base-year net spending of $936 million, works out to just 2.4 percent—a third less than the rolling average of medical inflation.

The formula for fiscal year 2019 is even tighter—medical inflation plus 4 points minus $85 million. At current spending levels, that will likely amount to a 2 percent cut in Medicaid drug spending.

Second, whether state spending ultimately exceeds the cap is not necessarily relevant under the law.

The statute is based not on actual spending but projected spending, as determined by the Health Department and budget director. These projections are supposed to be based on expenditures in the early quarters of the year or “other relevant information,” but the law gives little further guidance on how they should be set.

Third, the higher that spending is projected to go, the more the state can demand in rebates from companies to close the gap.

Fourth, the statute makes no reference to reconciling those projections with actual spending after the fiscal year is complete.

Fifth, the Health Department has broad discretion on which manufacturers to target and how much money to demand, leaving the industry in the dark as to what pricing standards it’s expected to follow. The state could choose to go after companies that have arbitrarily and excessively hiked their prices, or it could go after companies with the deepest pockets.

The combined effect of these provisions gives the state a powerful incentive to exaggerate projected growth as a way to maximize its leverage with pharmaceutical manufacturers and its savings for the state budget.

Saving money taxpayers is a legitimate goal, and the state has a duty keep all Medicaid spending, including spending on prescription drugs, under control.

However, the drug cap turns out not to be a uniform brake on rising costs, but a license to selectively squeeze discounts. Whether it uses that license responsibly and fairly remains to be seen.

About the Author

Bill Hammond

As the Empire Center’s senior fellow for health policy, Bill Hammond tracks fast-moving developments in New York’s massive health care industry, with a focus on how decisions made in Albany and Washington affect the well-being of patients, providers, taxpayers and the state’s economy.

Read more by Bill Hammond

You may also like

How Washington’s Budget Bill Will Affect Health Care in New York

UPDATE: The final version of the federal budget bill omitted a handful of provisions that had been included in earlier drafts. One would have penalized states that use their own money to provide coverage for undocumente Read More

Even With Federal Cuts, New York’s Health Funding Would Remain High

New York's health-care industry stands to lose billions of dollars in federal funding under the major budget bill being debated in Washington – a rare and jarring turn of events for a sector accustomed to steadily increas Read More

As Albany’s Session Ends, Watch for Rising Health Costs

Every session of the state Legislature brings a fresh crop of proposals that would drive up health-care costs, and 2025 is no exception. Here is a sampling of pending bills that, if Read More

House Budget Would Burst New York’s Essential Plan Bubble

The extraordinary cash bonanza associated with New York's Essential Plan – which has generated billions more than state officials were able to spend – would come to a crashing end under the budget bill advancing in Cong Read More

The House GOP’s Shrinking Budget Plan Could Still Cost New York Billions

The likely impact of federal health-care cutbacks has diminished in recent days as House Republican leaders backed away from some of their bigger-ticket proposals, reducing the estimated savings to $625 billion from previous figures of $715 billion and $8 Read More

How Medicaid ‘Expansion’ Changes Could Affect New York

As House Republicans consider cutbacks to federal Medicaid funding, their focus has turned to the so-called expansion population. Although the details of remain undetermined, the s Read More

New York’s Home Health Workforce Jumps by Another 10 Percent

New York's home health employment is continuing to soar, growing by 57,000 jobs or 10 percent from 2023 to 2024, according to newly released data from the U.S. Bureau of Labor Statistics. Read More

Immigrant Enrollment in ‘Emergency Medicaid’ Surges to 480,000

One of the biggest drivers of New York's Medicaid enrollment growth over the past decade has been "emergency Medicaid" for undocumented immigrants, newly released state records show. Read More